David M. Kern, MS

Articles by David M. Kern, MS

Treatment Patterns, Healthcare Utilization, and Costs of Chronic Opioid Treatment for Non-Cancer Pain in the United States

ByDavid M. Kern, MS,Siting Zhou, PhD,Soheil Chavoshi, MS,Ozgur Tunceli, PhD,Mark Sostek, MD,Joseph Singer, MD,Robert J. LoCasale, PhD

April 13th 2015

Healthcare utilization and costs increased in the 6 months after patients started opioid therapy for chronic pain; they then decreased but never reverted to baseline levels.

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

ByDavid M. Kern, MS,Stephanie DeVore, MSPH,Jennifer Kim, PharmD,Ozgur Tunceli, PhD,Bingcao Wu, MS,Boaz Hirshberg, MD

March 18th 2015

Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.

Latest Updated Articles

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease
Published: March 18th 2015 | Updated:
Treatment Patterns, Healthcare Utilization, and Costs of Chronic Opioid Treatment for Non-Cancer Pain in the United States
Published: April 13th 2015 | Updated:

David M. Kern, MS

Articles by David M. Kern, MS

Treatment Patterns, Healthcare Utilization, and Costs of Chronic Opioid Treatment for Non-Cancer Pain in the United States

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

Latest Updated Articles

Trending on AJMC

New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform

Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD

Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps

Medicare’s 3-Day Rule Reinstatement Lengthened Hospital Stays Without Cost, Outcome Benefits

FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads